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Concerns regarding specimen integrity have long been a major issue of urine drug testing 
due to acts of urine adulteration. At a high concentration, in vitro urine adulteration using 
sodium hypochlorite (bleach) produced false-negative results for 3,4-
methylenedioxymethamphetamine (MDMA) in CEDIA
®
 immunoassay screening with 5 
strong negative readings. However, these strong negative readings may act as a warning 
sign for further investigation of the sample where the detection of a unique marker in the 
form of N-chloroMDMA will suggest urine adulteration via bleach. Liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) identified N-chloroMDMA is a 
major product formed between hypochlorite and MDMA in urine. N-chloroMDMA was 10 
found stable at 4 °C for at least 10 h, but decomposed over time at room temperature (20 
°C) with MDMA being identified as one of its main decomposition products.      
 
1. Introduction 
According to the Australian Crime Commission Illicit Drug Data Report 2010-11 
1
, 15 
MDMA (3,4-methylenedioxymethamphetamine or ‘ecstasy’) was and remained the 
second most commonly used illicit drug in Australia, after cannabis.  
 
The act of adulteration has long been the primary challenge for urine drug testing. Such 
methods of urine adulteration (in vivo, in vitro and substitution 
2-6
) are carried out by 20 
individuals in an effort to “beat” a urine drug test, and thus, avoid detection of their drug 
use. Chemical (in vitro) adulteration — the primary focus of this study — involves the 
addition of foreign substances or chemicals (e.g. sodium chloride, liquid hand soap, 
vinegar, Visine
®
 eye drops 
4-8, ‘Urine Luck’, ‘Stealth’, ‘Klear’ and ‘UrineAid’ 2,6) to a 
 3 
urine specimen after it is collected. The presence of these foreign substances acts to either 
interfere with the screening and/or confirmatory methods 
2
, or convert the targeted drug 




Currently, the existing methods used to determine the integrity of a urine sample only 5 
allow for the detection of adulterated samples (e.g. commercial adulterant dipstick 
indicators 
2
 and sample integrity tests 
2,4,6
). However, there are no means to reveal what 
drug(s) of abuse was masked via adulteration. There is limited literature regarding 
chemical adulterants and their effects on the screening and/or confirmatory methods for 
amphetamine-type stimulants (ATS), let alone a study purely focused on the chemical 10 
adulteration of MDMA in urine. In this study, research was conducted into the chemical 
adulteration of MDMA in urine using sodium hypochlorite (NaOCl) - the active 
ingredient of bleach and a popular chemical adulterant. Of primary focus, the chemical 
reaction between NaOCl and MDMA was investigated to identify stable reaction 
products. The potential of using these identified stable reaction products as markers of 15 
MDMA abuse when urine specimens have been adulterated with bleach takes on an 
alternative and novel approach in the fight against urine adulteration.  The effect of 
bleach on the routine drug analysis of MDMA in urine was also investigated.  
 
2. Experimental  20 
2.1. Materials and reagents 
All reagents were of analytical grade unless indicated otherwise. MDMA hydrochloride 
(1 mg / mL in methanol) was sourced from Alltech-Applied Sciences (State College, PA, 
 4 
USA). Deuterated MDMA (MDMA-d5, 1 mg / mL in methanol) was supplied from 
Cerilliant (Austin, TX, USA). Working standard solutions of MDMA (100, 10 and 5 μg / 
mL) and MDMA-d5 (10 μg / mL) were prepared by appropriate dilution with methanol. 
Pentafluoropropionic acid (PFPA, 99 %) and two strengths of sodium hypochlorite 
(NaOCl) were purchased from Sigma-Aldrich (St Louis, MO, USA). The stronger NaOCl 5 
reagent (referred to as “strong NaOCl”) contained 10  15 % available chlorine, while the 
other (referred to as “weak NaOCl”) contained 5  10 % available chlorine. NaOCl 
concentration was determined spectrophotometrically at 0.319 M (“strong NaOCl”) and 
0.029 M (“weak NaOCl”) using a molar absorbance coefficient (ε) of 350 M-1 cm-1 for 
the absorbance of 
–
OCl at 292 nm 
9
. A stock solution of 1 M ammonium formate was 10 
prepared and stored in a refrigerator (4 °C) before use. 
 
Blank urine samples were sourced from healthy individuals. Real urine samples positive 
for MDMA were obtained from the Toxicology Unit, Pacific Medicine Laboratory 
Services (PaLMS), and the Toxicology and Forensic Unit, ACT Government Analytical 15 
Laboratory (ACTGAL) following removal of sample identification. All urine samples, 
along with all standards and solutions when not in use, were stored in a refrigerator (4 
°C). 
 
2.2. LC-MS/MS  20 
The Agilent MassHunter Data Acquisition Software (version B.02.00, Agilent 
Technologies Inc., Palo Alto, CA, USA) was used to operate the LC-MS/MS 
instrumentation, consisting of the Agilent 1200 series LC system connected to the Agilent 
 5 
6460 Triple Quad LC/MS via an electrospray ionisation (ESI) interface. Chromatographic 
separation was achieved on an XBridge (Waters Corporation, Ireland) C18 column (150 
mm x 4.6 mm, 3.5 µm) maintained at 25 °C at a flow rate of 0.3 mL / min. Gradient 
elution was employed using the mobile phases of 2 mM ammonium formate solution in 
water (solvent A) and acetonitrile (solvent B). The gradient elution profile was as 5 
follows: solvent B increased from 40 % to 70 % in 10 min and maintained at 70 % for 4 
min; followed by 95 % solvent B for 6 min before equilibrating with 40 % solvent B for 
10 min totalling a run time of 30 min. The following MS conditions were used; 
fragmentor voltage 90 V; gas flow 10 L / min for both drying gas (300 °C) and sheath gas 
(350 °C), nebulizer gas pressure 35 psi; capillary voltage 3500 V and nozzle voltage 1000 10 
V. The injection volume was 1 µL and samples were analysed in full scan mode (m/z 50 
 450) or selected reaction monitoring (SRM) mode using positive ionisation. Three 
SRM transitions (Table 1) were optimised and monitored for MDMA and the reaction 
product, which was later identified (refer to section 3.2).  
 15 
2.2.1. Reaction between hypochlorite and MDMA 
The reaction between hypochlorite and MDMA at room temperature was first performed 
in water followed by in urine. The reaction in water consisted of final concentrations of 
MDMA and NaOCl at 10 μg / mL and 1.6 x 10-3 M, respectively. For the reaction in 
urine, blank urine was centrifuged at 3400 g for five minutes. The supernatant was 20 
filtered through a 0.45 μm syringe filter (13 mm PTFE, hydrophilic, MicroAnalytix, 
Australia) and the reaction mixture
 contained 10 μg / mL MDMA and 9.6 x 10-2 M 
NaOCl. Additionally, a real urine sample containing MDMA obtained from ACTGAL 
 6 
was adulterated with NaOCl (at 1.4 x 10
-2
 and 9.6 x 10
-2
 M final concentrations). All 
reaction mixtures were immediately analysed by LC-MS/MS in either full scan mode or 
in SRM mode.    
  
2.2.2. Stability of major reaction product(s) 5 
The stability of major reaction products was assessed through a number of kinetic 
experiments (Table 2), which were only performed in the urine matrix. Different MDMA 
concentrations (1 or 10 μg / mL), NaOCl concentrations (1.4 x 10-2 or 9.6 x 10-2 M) and 
auto-sampler temperature conditions (4 or 20 °C) were tested. Each kinetic experiment 
involved blank urine being treated as above, which was then used in the preparation of 10 
the ‘stock reaction mixture’. Blank urine from the same donor was used across all kinetic 
studies. Each stock reaction mixture was injected and hence, monitored at every 30 min 
for the duration of 5 h, except for the stock reaction mixture for Kinetic Experiment 4 
(which was monitored over 10 h and was repeated using blank urine from another donor). 
Appropriate matrix matched calibration standards (Kinetic Experiments 1-2: 0.15, 0.30, 15 
0.45, 0.60, 0.75 and 1.00 μg / mL, Kinetic Experiments 3-4: 0.15, 0.30, 0.45, 2.50, 5.00 
and 10.00 μg / mL) and blanks were prepared and analysed. The calibration standards 
included the addition of NaOH to simulate the pH environment in the stock reaction 
mixtures. The volume of NaOH added correlated to the NaOCl volume added in the 
respective stock reaction mixture. Kinetic Experiments 2  4 used 0.15 M NaOH, while 20 
Kinetic Experiment 1 used 0.5 M NaOH. All samples were analysed by LC-MS/MS in 
SRM mode.  
 
 7 
2.2.3. Assessment of matrix effects 
Matrix effects were assessed using the post-column infusion method. Post-column, 5 μg / 
mL MDMA in mobile phase (50 % A:50 % B) was continuously infused through a ‘tee’ 
using a Harvard Apparatus (South Natick, Massachusetts, USA) syringe pump set at a 
flow rate of 25 μL / min and syringe diameter of 4.3 mm. The following 1 μL injections 5 
were injected into the LC system: mobile phase, blank urine, blank urine containing 9.6 x 
10
-2
 M NaOCl (i.e. 30 μL strong NaOCl reacted with 70 μL blank urine) and blank urine 
containing 4.5 x 10
-2
 M NaOH (i.e. 30 μL of 0.15 M NaOH reacted with 70 μL blank 
urine). Blank urine from two donors was used for the matrix effects experiment. All 
samples were analysed in SRM mode. 10 
 
2.3. Immunoassay screening testing 
Immunoassay screening testing was performed using the CEDIA
®
 Amphetamine / 
Ecstasy Assay test kit together with 0.3 and 0.5 μg / mL calibrators supplied by Thermo 
Fisher Scientific (Scoresby, Vic, Australia). The CEDIA
®
 screening was performed 15 
according to the manufacturer’s instructions, on an Olympus AU 2700 analyser 
(Olympus America Inc., Melville, NY). The test samples consisted of blank urine spiked 
with MDMA and NaOCl. Three concentrations of MDMA (0.3, 1.0 and 10 μg / mL) were 
tested using two concentrations of NaOCl (1.4 x 10
-2
 and 9.6 x 10
-2
 M). Additionally, a 
real urine sample containing MDMA obtained from PaLMS was adulterated with two 20 
lower concentrations of NaOCl (1.3 x 10
-2
 and 7.4 x 10
-2
 M). Appropriate control samples 
were prepared and differed from the reaction samples with the addition of 0.15 M NaOH 
 8 
in place of NaOCl. Each sample was prepared in triplicate, apart from blanks which were 
prepared in duplicate (Table 3). 
 
2.4. GC-MS confirmatory testing  
2.4.1. Sample preparation and derivatisation 5 
The MDMA and NaOCl concentrations that were studied in the stability experiments 
(section 2.2.2.) were also applied for GC-MS testing. The samples, prepared in duplicate, 
consisted of reacting 1 μg / mL MDMA with the lower NaOCl concentration of 1.4 x 10-2 
M in urine, while 10 μg / mL MDMA was reacted with the higher NaOCl concentration 
of 9.6 x 10
-2
 M in urine. Different reaction times were tested by leaving the samples to 10 
react for 10 min and 4 h at room temperature. Appropriate blanks and calibration 
standards (0.05, 0.15, 0.30, 0.45, 1.00, 5.00, 10.00 μg / mL) were also prepared in urine. 
Calibration standards were prepared in triplicate. Ten microlitres of 10 μg / mL MDMA-
d5 (internal standard) solution was then added to all before liquid-liquid extraction (LLE). 
LLE involved adding 100 μL of 5 M NaOH and 2 mL of dichloromethane to each 15 
followed by gentle mixing. An aliquot (1 mL) of the dichloromethane layer was 
quantitatively transferred into a recovery vial. Following the addition of 50 μL of 10 % 
concentrated hydrochloric acid in methanol, each extract was evaporated to dryness under 
a gentle N2 stream at 30 °C. Derivitisation was performed at 75 °C for 30 min with the 
addition of 100 μL ethyl acetate and 50 μL of PFPA. Following the removal of the 20 
derivatising reagent under a gentle stream of N2 at 30 °C, the derivatives were 




GC-MS analysis was conducted on the Agilent 6890 series GC system coupled to the 
Agilent 5973 network MSD (mass selective detector). Separation was performed on the 
Zebron ZB-5MS capillary column (30 m x 0.25 mm i.d. x 0.25 μm, 5 % polysilarylene – 
95 % polydimethylsiloxane, Phenomenex Inc., Torrance, CA, USA) and samples (1 μL) 5 
were injected in the splitless mode. Helium was used as the carrier gas at a flow rate of 1 
mL / min. The oven temperature program was as follows: an initial temperature of 60 °C 
held for 1 min, ramped to 200 °C at 30 °C / min, and then to 300 °C at 70 °C / min with 
a final temperature hold for 5 min totalling a run time of 12.1 min. The MS was operated 
in selected ion monitoring (SIM) acquisition mode. The following ions were monitored: 10 
MDMA 135, 162, 204 (quantifying ion) and 339; MDMA-d5 163, 208 (quantifying ion) 
and 344.  
 
3. Results and Discussion  
3.1 Reaction profile between MDMA and hypochlorite 15 
Water provided a relatively matrix-free medium for studying the reaction. Hence, a 
greater concentration of NaOCl was required in its urinary reaction with MDMA. 
Comparing the LC-MS full scan chromatograms obtained for the relevant blanks and 
NaOCl reacted MDMA standards in both water and urine (Figure 1) revealed there was 
one obvious major reaction product (Figure 1c and d), eluting at approximately 18.5 min. 20 
Both reactions carried out in water and in urine appeared to completely oxidise MDMA 
in the sample, as indicated by the absence of a peak at approximately 9.7 min – the time 
at which MDMA eluted in both water (Figure 1a) and in urine (Figure 1b). A similar 
 10 
result was obtained when a real urine specimen containing MDMA was adulterated with 
NaOCl (data not shown).   
 
3.2. Identification of major reaction product(s) 
Comparisons between the mass spectra obtained for the unknown reaction product from 5 
the reaction between MDMA and NaOCl performed in the two different matrices (i.e 
water and urine), showed that they were the same product. The mass spectra obtained for 
MDMA and the unknown reaction product (Figure 2) reveal similarities in terms of 
common fragmentation ions (m/z 58, 105, 135 and 163) found in both mass spectra. With 
regards to the unknown reaction product structural elucidation, the common 10 
fragmentation ions suggest it has a structure similar to MDMA. Apart from the 
fragmentation ions of m/z 58, 105, 135 (base peak) and 163, closer inspection of the mass 
spectrum also reveals an additional and hypothesised molecular ion [M + H]
+
 peak 
occurring at m/z 228 and a characteristic [M + H + 2]
+
 chlorine isotopic cluster observed 
(m/z 228 and m/z 230, respectively; Figure 2c) indicative of a mono-chlorinated MDMA 15 
reaction product. There are only two possible positions at which the chlorine atom could 
be substituted onto the MDMA molecule: (i) either on the benzene ring or (ii) on the 
amine moiety of MDMA. Lewis et al. 
10
 confirmed the identity of a chlorinated analog of 
MDMA as 2-chloroMDMA. In the study, the mass spectrum of 2-chloroMDMA 
exhibited the two ions of m/z 169 and 196, which showed the characteristic A + 2 20 
chlorine isotopic cluster, both of which are absent in the mass spectrum results of this 
study. In a more recent study conducted by Maresova et al. 
11
, a chlorinated MDMA 
product, hypothesised as 6-chloroMDMA, was detected and similarly, showed the ion of 
 11 
m/z 169 exhibiting the characteristic A + 2 chlorine isotopic cluster. Thus, it was 
concluded that the unknown reaction product was most likely a chloramine species in the 
form of N-chloroMDMA (i.e. the chlorine substitution took place on the amine moiety of 
MDMA). The proposed structure and detailed fragmentation pattern of the reaction 
product are illustrated in Figure 3. Product ion scan and precursor ion scan experiments 5 
(data not shown) supported the proposed fragmentation pathways. 
 
3.3. Stability of N-chloroMDMA 
The calibration obtained for the range of 0.15  1.00 μg / mL and 0.15  10.00 μg / mL 
achieved coefficient of determination (r2) values of 0.9697  0.9883 and 0.9961  0.9998, 10 
respectively. Across all kinetic studies, the reaction between NaOCl and MDMA was fast 
with N-chloroMDMA being formed after two minutes. The effects of temperature, 
MDMA concentration and NaOCl concentration were investigated. Results from Kinetic 
Experiment 3 (20 °C, i.e. room temperature) showed two evident trends: the peak area of 
N-chloroMDMA slowly decreased over time, while the concentration of MDMA slowly 15 
increased over time (Figure 4). Approximately 41 % of MDMA was detected and 
remained at the end of the 5 h kinetic experiment. Kinetic Experiment 4 (4 °C, i.e. 
refrigeration temperature) involved using blank urine from two different donors. The 
results were consistent with each other and collectively showed remarkably different 
findings from Kinetic Experiment 3. It was found that MDMA was destroyed and 20 
unquantifiable, but the peak area for N-chloroMDMA remained relatively stable (7  9 % 
RSD) throughout both of the 10 h monitored periods (data not shown). Thus, this shows 
that N-chloroMDMA was unstable at room temperature and possibly reverted back into 
 12 
MDMA, but was relatively stable at refrigeration temperature. Potentially, this shows that 
N-chloroMDMA could be used as a marker of MDMA abuse when urine specimens have 
been adulterated with bleach, if the collected urine sample is stored at 4 °C immediately 
and up until analysis via LC-MS/MS.  
 5 
In Kinetic Experiment 3, NaOCl was found to oxidise approximately 59 % of the MDMA 
starting concentration (over a 5 h period). Although N-chloroMDMA was shown to 
decompose and possibly revert back into MDMA, this process cannot possibly account 
for the 59 % alone. It is well documented in literature that many chloramine species are 
unstable and undergo various secondary reactions including decomposition and 10 
disproportionation 
12-14
. Thus, it is hypothesised that N-chloroMDMA decomposes to 
other products such as an aldehyde in addition to MDMA. However, no other products 
were detected under the experimental conditions employed. LC-MS/MS was also 
performed in negative ionisation mode, but failed to detect any additional reaction 
products from the reaction mixture. More research is required to investigate this issue.  15 
 
Kinetic Experiments 1 and 2 involved a relatively low starting MDMA concentration of 1 
μg / mL. The results of Kinetic Experiment 1 (using a low NaOCl concentration) were 
similar to Kinetic Experiment 3 where the peak area of N-chloroMDMA slowly 
decreased over the 5 h period. For Kinetic Experiment 2 (using a high NaOCl 20 
concentration), N-chloroMDMA was detected in the first injection (i.e. two minutes into 
the reaction), but was not detected in the second injection (i.e. 32 minutes into the 
reaction) nor in any subsequent injections. In both experiments, MDMA was not 
 13 
quantifiable and NaOCl effectively oxidised MDMA to below the cut-off concentration 
for confirmatory testing (0.15 μg / mL) 15. However, N-chloroMDMA was detected in 
both experiments and this shows the potential of N-chloroMDMA being used as a marker 
of MDMA abuse in bleach adulterated urine specimens.  
 5 
3.4. Matrix effects 
Using continuous post-column infusion, it was clear that there was ion suppression 
encountered for the quantitation of MDMA. Although the post-column infusion method 
does not fully quantitate matrix effects compared to the method utilised by Matuszewski 
et al 
16, 17
, approximate ion suppression percentages were calculated as 8 % for urine and 10 
9.5 % for both the addition of NaOH and NaOCl in urine. The agreement of the ion 
suppression percentages encountered for NaOH and NaOCl in urine supports the addition 
of NaOH in calibration standards in this study to calculate the concentration of MDMA 
remaining in reaction samples. Ion suppression was also evident at the retention time of 
N-chloroMDMA, but was not calculated as N-chloroMDMA was not quantified 15 
throughout this study.  
 
3.5. Effect of bleach on the routine drug analysis of MDMA in urine  
In a majority of laboratories and for routine urine drug testing, immunoassays are often 
employed for screening tests, followed by GC-MS confirmatory testing 
18, 19
. The lowest 20 
concentration utilised with the CEDIA
® 
immunoassays in this study was 0.30 μg / mL 
MDMA as this is the recommended concentration cut-off value for the ATS screening 
tests 
15
. Only the use of the higher concentration of NaOCl effectively produced false-
 14 
negative results across all samples (Table 3). Interestingly, the CEDIA
®
 immunoassay 
readings for all the false-negative samples are similar to each other at approximately – 
0.85. Thus, a reading of – 0.85 may potentially indicate a sample has been adulterated 
with a high concentration of bleach to conceal MDMA use and act as a warning sign for 
further investigation of the sample. The false-negative results produced in this study are 5 
consistent with findings from other similar studies. Bleach has previously been 
demonstrated to produce false-negative results across the EMIT 
7
 (enzyme multiplied 
immunoassay technique) and FPIA 
20
 (fluorescence polarisation immunoassay) systems. 
The primary mechanism of action of bleach is oxidation 
2, 4, 5





 postulated that bleach interferes with EMIT through oxidising NADH, which 10 
decreases its absorbance at 340 nm. Additionally, the alkaline pH changes caused by 
bleach can alter binding and reaction rates 
2, 7
, producing false-negative results for EMIT, 
CEDIA
®
 and FPIA 
2
. The study conducted by Mikkelson and Ash 
7
 also showed that 
bleach caused concentration-dependent interference for the EMIT for amphetamines. In a 
more recent study by Chou and Giang 
20
, bleach was evaluated as having a moderate to 15 
high potential to produce a false-negative result for FPIA for amphetamines. 
 
For GC-MS analysis, the calibration obtained in the range of 0.05  10.0 μg / mL 
achieved a r
2
 values of 0.999. The results summarised in Table 4 show that the time the 
samples were left to react did not have a significant effect on the final percentage loss of 20 
MDMA, with a reported 11 % and 10 % MDMA loss in GC-MS Experiments 1 and 2, 
and 24 % and 20 % loss in GC-MS Experiments 3 and 4. Although no false-negative 
results were obtained from these tests, a false negative result might be possible if the 
 15 
initial MDMA concentration is low and around the cut-off concentration at 0.15 μg / mL. 
To test this,  blank urine samples spiked with MDMA at  0.15 μg / mL were exposed to 
NaOCl at concentrations of 1.16 x 10
-2
 and 1.90 x 10
-2
 M. GC-MS analysis showed that  
NaOCl  oxidised the starting MDMA concentrations significantly below the cut-off 
concentration value (data not shown), with a reported  MDMA loss ranging from 53 - 64 5 
%. These oxidation percentages are similar to those reported by Chou et al. 
21
, who 
observed a 36  63% decrease in a sample’s initial amphetamines (methamphetamine, 
amphetamine, MDMA and 3,4-methylenedioxyamphetamine) concentration with the use 
of bleach as an adulterant. In the study, the amphetamine concentrations in the urine 
samples were approximately 0.625 μg / mL, representing 125 % of the Taiwanese cut-off 10 
concentration value. Bleach effectively produced false-negative results for all MDMA 
samples and Chou et al. 
20
 attributed the effectiveness of bleach as an adulterant to its 
ability to degrade analytes and / or deactivate the derivatising agent through oxidation 
before and / or during sample preparation, in addition to the dilution effect from adding 
excess liquid to a sample.  15 
 
It is worth noting that in our study the net loss of MDMA in urine following NaOCl 
exposure was not always comparable between results obtained from the LC-MS/MS and 
the GC-MS analysis even though the reaction conditions were maintained as close as 
possible. This may be attributed to the different sample preparation procedures used by 20 
the two analytical methods and the elevated temperatures (i.e. injection port and column 
temperatures) applied in GC-MS analysis. In LC-MS/MS, samples were analysed 
immediately without any further sample preparation, while in GC-MS, sample analysis 
 16 
was only possible following a sequence of sample preparation steps including LLE 
extraction, solvent evaporation and derivatisation. 
 
4. Conclusion 
The findings of this study identified one major reaction product, N-chloroMDMA, arising 5 
from the oxidation reaction of MDMA in urine after being exposed to bleach. N-
chloroMDMA was found to be relatively stable at 4 °C and can not only potentially 
indicate MDMA use, but also urine adulteration via bleach. However, N-chloroMDMA 
was unstable at 20 °C and decomposed into MDMA as well as possibly other 
degradation products. At a high concentration, bleach was shown to be an effective 10 
adulterant producing false-negative results across CEDIA
® 
immunoassay testing with 
strong negative readings. However, these readings were all quite similar with a value of – 
0.85, which may act as a warning sign for further investigation of the sample. 
Confirmatory analysis of these false-negative specimens for the presence of MDMA by 
LC-MS/MS or GC-MS may reveal MDMA abuse.  15 
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Tables and Figures 
 
Table 1. Optimised SRM transitions monitored for MDMA and the reaction product (N-chloroMDMA). 
Product 
Precursor ion m/z 
(amu) 
Product ion m/z 
(amu) 
Collision Energy (V) 
MDMA 
194 163 6 
194 135 20 
194 105 20 
Reaction product 
(N-chloroMDMA) 
228 163 6 
228 135 20 
228 105 25 
 
 20 
Table 2. Kinetic experiments performed on the stability of MDMA and the reaction product (N-chloroMDMA) formed reacting  MDMA  with  
NaOCl
*
.   
* 
Each experiment was performed for 5 h, except Kinetic Experiment 4 which was performed over 10 h.  
** 
Weak NaOCl: 5 – 10% chlorine; strong NaOCl: 10 – 15% 
 
  




Conc. (μg / mL) 
Final NaOCl 
Conc. ( x 10
-2




10 μL of 10 μg / mL MDMA reacted with 49.5 μL 
weak NaOCl in 40.5 μL of urine 
1 1.4 20 
2 
10 μL of 10 μg / mL MDMA reacted with 30 μL 
strong NaOCl in 60 μL of urine 
1 9.6 20 
3 
10 μL of 100 μg / mL MDMA reacted with 30 μL 
strong NaOCl in 60 μL of urine 
10 9.6 20 
4 
10 μL of 100 μg / mL MDMA reacted with 30 μL 
strong NaOCl in 60 μL of urine 
10 9.6 4 
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Table 3. Summary of immunoassay results. 




Conc. (μg / mL) 










Ave. Assay Reading 




Reaction 1 1852 0.30 1.4 0 1.12 (8.78) Pos 
Reaction 2 1340 0.30 9.6  0 -0.83 (-4.89) Neg
*
 
NaOH control 1 1852 0.30 0 0.7  1.27 (1.98) Pos 
NaOH control 2 1340 0.30 0 4.5 1.29 (4.32) Pos 
MDMA control 1940 0.30 0 0 1.22(4.50) Pos 
2 
Reaction 1 1712 1.00 1.4  0 2.53 (4.68) Pos 
Reaction 2 1200 1.00 9.6 0 -0.85 (0.00) Neg
*
 
NaOH control 1 1712 1.00 0 0.7 2.60 (0.54) Pos 
NaOH control 2 1200 1.00 0 4.5 2.70 (1.61) Pos 
MDMA control 1800 1.00 0 0 2.62 (2.50) Pos 
3 
Reaction 1 1712 10.00 1.4  0 3.32 (1.98) Pos 
Reaction 2 1200 10.00 9.6  0 -0.85 (0.00) Neg
*
 
NaOH control 1 1712 10.00 0 0.7 3.50 (1.29) Pos 
NaOH control 2 1200 10.00 0 4.5 3.60 (0.98) Pos 
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Reaction 1 500 0.19 1.3  0 0.59 (3.39) Pos 
Reaction 2 500 0.16 7.4  0 -0.85 (0.00) Neg
*
 
NaOH control 1 500 0.19 0 0.6 1.70 (0.00) Pos 
NaOH control 2 500 0.19 0 3.5 0.60 (0.00) Pos 
Blanks 
NaOCl 1 1912 0 1.4  0 -0.05 (-141.42) Neg 
NaOCl 2 1400 0 9.6 0 -0.85 (0.00) Neg 
Urine 2000 0 0 0 0.04 (0.00) Neg 
*
 Sample produced a false-negative result. 
†
 All control samples were prepared by the addition of 0.15 M NaOH in place of NaOCl. i.e. for Experiments 1  3, 88 μL NaOCl or 
NaOH was added to  samples ‘Reaction 1’ or ‘NaOH control 1’, respectively. Similarly, 600 μL NaOCl or NaOH was added to samples 
‘Reaction 2’ or ‘NaOH control 2’, respectively.  
‡
 For Experiment 4, an authentic urine sample containing 0.203 μg / mL MDMA (determined by the testing laboratory at the 
Toxicology Unit, PaLMS, NSW, Australia) was used. Samples ‘Reaction 1’ or ‘NaOH control 1’ had 22 μL NaOCl or NaOH added, 
respectively. Similarly, samples ‘Reaction 2’ or ‘NaOH control 2’ had 150 μL NaOCl or NaOH added, respectively. 
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Time sample was 
left to react (min) 
Final MDMA 





1 10 0.89 11 
2 240 0.88 12 
10.0 9.6 
3 10 7.58 24 
4 240 8.04 20 
 
*
 All GC-MS experimental results (average, n = 2) returned positive as the cut-off concentration for 



















Figure 1. Comparison between the LC-MS full scan chromatograms obtained for: (a) MDMA in water, (b) MDMA in urine, (c) MDMA reacted 












Figure 2. (a) MS spectrum obtained for MDMA in urine with its detailed fragmentation pattern 
(insert) and (b) MS spectrum obtained for the unknown reaction product with (c) an emphasis on 
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Figure 4. Data obtained for Kinetic Experiment 3 (i.e. 10 μL of the 100 μg / mL MDMA was reacted with 30 μL strong 
NaOCl in 60 μL of urine) performed at 20 °C for 5 h. Primary axis plots N-chloroMDMA peak area over time. Secondary 
axis plots MDMA concentration (μg / mL) over time.   
  
 
